Colorectal cancer remains a major clinical challenge, and dual targeting of PTPN1 and PTPN2 represents a promising strategy to modulate conserved phosphatase signaling relevant to tumor biology and immune regulation. This evidence concerns the gene PTPN2 and neoplasm.